Cipher Ground

Cipher Ground is a biotechnology company focused on accelerating drug discovery through its proprietary Cipher-Seq platform. The company utilizes advanced DNA-encoded library (DEL) technology combined with high-throughput sequencing and machine learning to identify novel small molecule candidates. Their primary focus is on oncology, specifically targeting proteins that have historically been considered 'undruggable.' By integrating chemical diversity with genomic-scale screening, Cipher Ground aims to streamline the path from target identification to lead optimization. The company is headquartered in New Jersey and operates as a private entity dedicated to precision medicine.